MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent-Reference-Cited by-同舟云学术

MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent

Published:2021-10-22 Issue:12 Volume:18 Page:4543-4552
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Wang Qi¹,Huang Lei¹,Zhu Xuna¹,Zhou Yan¹,Wang Jialing¹,Su Danke¹,Liu Lidong¹^ORCID

Affiliation:

1. Medical Imaging Department; Guangxi Key Clinical Specialty (Medical Imaging Department); Dominant Cultivation Discipline of Guangxi Medical University Cancer Hospital (Medical Imaging Department), Guangxi Medical University Cancer Hospital, Nanning 530021, P. R. China

Funder

Natural Science Foundation of Guangxi Province

Research institute of innovative think-tank in Guangxi Medical University

Guangxi Clinical Research Center for Medical Imaging Construction

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.1c00749

Reference35 articles.

1. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO